Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
---|
Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
---|
Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
---|
Akebia Therapeutics (NASDAQ:AKBA) reported its Q4 earnings results on Thursday, March 14, 2024 at 04:15 PM.
Here's what investors need to know about the announcement.
Akebia Therapeutics beat estimated earnings by 100.0%, reporting an EPS of $0.0 versus an estimate of $-0.04.
Revenue was up $1.02 million from the same period last year.
Last quarter the company missed on EPS by $0.0 which was followed by a 5.0% drop in the share price the next day.
Here's a look at Akebia Therapeutics's past performance:
Quarter | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 |
---|---|---|---|---|
EPS Estimate | -0.08 | -0.02 | -0.15 | -0.19 |
EPS Actual | -0.08 | -0.06 | -0.14 | -0.04 |
Revenue Estimate | 48.18M | 59.10M | 46.68M | 47.40M |
Revenue Actual | 42.05M | 56.38M | 40.13M | 55.18M |
To track all earnings releases for Akebia Therapeutics visit their earnings calendar here.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
Posted In: AKBA